Latest Information Update: 03 Dec 2007
At a glance
- Originator Keryx Biopharmaceuticals
- Mechanism of Action Immunoglobulin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 03 Dec 2005 Discontinued - Preclinical for Asthma in Israel (unspecified route)
- 12 Jun 2001 No-Development-Reported for Asthma in Israel (Unknown route)
- 15 Dec 1997 New profile